XFOR Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

a month ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

a month ago - By: Zacks Investment Research - Mentions: MGTX

MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

a month ago - By: Zacks Investment Research - Mentions: ALVO

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: TECH

Techne (TECH) Meets Q1 Earnings Estimates

a month ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

a month ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

a month ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

a month ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

a month ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

a month ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

3 months ago - By: Stocktwits

X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial

3 months ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

3 months ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

4 months ago - By: Benzinga - Mentions: SNGX VKTX PPCB TELA ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

4 months ago - By: Benzinga - Mentions: IBIO SNGX LIXT ALTS ...

12 Health Care Stocks Moving In Monday's After-Market Session

4 months ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Stocktwits - Mentions: VTWG URTY

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

4 months ago - By: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

4 months ago - By: X4 Pharmaceuticals

X4 PHARMACEUTICALS INC (XFOR) Stock News

XFOR Latest News, Press Relases and Analysis

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates

Techne (TECH) Meets Q1 Earnings Estimates

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Monday's After-Market Session

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership